NASDAQ:ABOS
Acumen Pharmaceuticals, Inc.
- Stock
Last Close
1.90
06/11 21:09
Market Cap
137.58M
Beta: -
Volume Today
129.63K
Avg: 100.61K
PE Ratio
−3.53
PFCF: −3.92
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 70K - | 45.50K 35% | 99.50 - | |||
average payables | 377K - | 809.50K 114.72% | 1.36M 68.50% | 1.51M 10.67% | ||
average receivables | 69.50K - | 54.50K 21.58% | 112.40K - | |||
book value per share | -0.40 - | -0.65 62.79% | 11.23 1,830.24% | 4.65 58.59% | 5.49 18.13% | |
capex per share | -0.00 - | -0.00 98.84% | -0.00 89.11% | |||
capex to depreciation | -10 - | -0.95 90.47% | -0.11 88.02% | |||
capex to operating cash flow | 0.00 - | 0.00 105.65% | 0.00 89.35% | |||
capex to revenue | ||||||
cash per share | 0.23 - | 1.53 568.15% | 9.68 533.81% | 4.37 54.83% | 5.01 14.53% | |
days of inventory on hand | ||||||
days payables outstanding | 2.74K - | |||||
days sales outstanding | 6.45 - | 27.71 329.37% | ||||
debt to assets | 0.00 - | 0.10 18,471.95% | ||||
debt to equity | 0.00 - | 0.12 20,616.51% | ||||
dividend yield | ||||||
earnings yield | -0.01 - | -0.01 6.84% | -1.34 10,436.10% | -0.18 86.22% | -0.28 51.98% | |
enterprise value | 569.35M - | 532.12M 6.54% | 13.43M 97.48% | 89.25M 564.74% | 150.82M 68.98% | |
enterprise value over ebitda | -74.35 - | -62.62 15.78% | 0.22 100.35% | -1.98 1,008.25% | -2.47 24.94% | |
ev to operating cash flow | -83.51 - | -71.43 14.47% | -0.75 98.95% | -2.54 239.64% | -3.50 37.94% | |
ev to sales | 335.50 - | 370.56 10.45% | ||||
free cash flow per share | -0.24 - | -0.26 9.27% | -0.90 245.16% | -0.87 3.09% | -0.89 1.91% | |
free cash flow yield | -0.01 - | -0.01 9.27% | -0.13 926.28% | -0.16 21.32% | -0.23 43.31% | |
graham net net | -0.42 - | -0.67 57.42% | 9.43 1,513.03% | 4.18 55.64% | 4.13 1.35% | |
graham number | 1.57 - | 1.93 23.15% | 47.83 2,376.10% | 10.21 78.65% | 11.54 12.99% | |
income quality | 0.86 - | 1.02 17.95% | 0.18 82.45% | 0.82 359.46% | 0.82 0.25% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | 19.00 - | 105.23 453.86% | ||||
interest debt per share | -0.06 - | 0.62 1,207.65% | ||||
inventory turnover | ||||||
invested capital | 0.00 - | 0.12 20,616.51% | ||||
market cap | 575.90M - | 575.90M 0% | 135.59M 76.46% | 219.25M 61.70% | 186.66M 14.86% | |
net current asset value | -11.56M - | -18.59M 60.77% | 193.51M 1,140.90% | 172.52M 10.85% | 203.46M 17.94% | |
net debt to ebitda | 0.86 - | 5.15 502.10% | -1.98 138.51% | 2.88 245.39% | 0.59 79.62% | |
net income per share | -0.27 - | -0.26 6.84% | -9.06 3,443.49% | -1.00 88.99% | -1.08 8.08% | |
operating cash flow per share | -0.24 - | -0.26 9.27% | -0.90 244.39% | -0.87 3.31% | -0.89 2.32% | |
payables turnover | 0.13 - | |||||
receivables turnover | 56.57 - | 13.17 76.71% | ||||
research and ddevelopement to revenue | 5.05 - | 5.57 10.20% | ||||
return on tangible assets | -1.07 - | -0.16 84.65% | -0.79 378.49% | -0.21 73.90% | -0.17 17.98% | |
revenue per share | 0.06 - | 0.05 15.38% | ||||
roe | 0.69 - | 0.39 42.78% | -0.81 304.80% | -0.21 73.43% | -0.20 8.51% | |
roic | 0.68 - | 0.43 37.38% | 0.49 16.04% | -0.23 145.78% | -0.21 9.25% | |
sales general and administrative to revenue | 0.55 - | 0.94 72.41% | ||||
shareholders equity per share | -0.40 - | -0.65 62.79% | 11.23 1,830.24% | 4.65 58.59% | 5.49 18.13% | |
stock based compensation to revenue | 0.10 - | 0.11 4.59% | ||||
tangible asset value | -11.42M - | -18.59M 62.79% | 225.18M 1,311.25% | 188.78M 16.17% | 266.97M 41.42% | |
tangible book value per share | -0.40 - | -0.65 62.79% | 11.23 1,830.24% | 4.65 58.59% | 5.49 18.13% | |
working capital | 5.84M - | 38.06M 552.19% | 193.51M 408.42% | 172.52M 10.85% | 233.64M 35.43% |
All numbers in USD (except ratios and percentages)